Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Promising rationally derived combination therapy with PI3K and CDK4/6 inhibitors.

Cancer cell - 14 Jul 2014

Muranen Taru, Meric-Bernstam Funda, Mills Gordon B

Abstract excerpt

In this issue of Cancer Cell, Vora and colleagues demonstrate that persistent CDK4 and pRB activation underlie acquired resistance to phosphatidylinositol 3-kinase (PI3K) inhibitors in breast cancer cell lines, suggesting that clinical evaluation of rational combination therapy with PI3K and CDK4/6 inhibitors to mitigate resistance to PI3K inhibition is warranted.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Breast Neoplasms
Share to Class I Phosphatidylinositol 3-Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclin-Dependent Kinase 4

Share to Cyclin-Dependent Kinase 6

Share to CDK4 gene

Share to Mutation

Share to Phosphoinositide-3 Kinase Inhibitors

Source

Identifiers

PMID: 25026206
DOI: 10.1016/j.ccr.2014.06.020

Genes

CDK4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Promising rationally derived combination therapy with PI3K and CDK4/6 inhibitors.PMID 25026206Read ↗

CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors.Semantic proximity Read ↗

The Promise of Combining Inhibition of PI3K and PARP as Cancer TherapySemantic proximity Read ↗

The phosphoinositide 3-kinase pathway and therapy resistance in cancerSemantic proximity Read ↗

Inavolisib-based Combination Therapy for the Treatment of PIK3CAMutated HR+/HER2- Breast Cancer: An Overview.Semantic proximity Read ↗

Phosphoinositide 3-Kinase (PI3K) Inhibitors and Breast Cancer: An Overview of Current AchievementsSemantic proximity Read ↗

Targeting PI3K Signaling in Combination Cancer Therapy.Semantic proximity Read ↗

PI3K inhibition in breast cancer: Identifying and overcoming different flavors of resistance.Semantic proximity Read ↗

PI3K-AKT-mTOR inhibitors in breast cancers: From tumor cell signaling to clinical trialsSemantic proximity Read ↗

Targeting mTOR to overcome resistance to hormone and CDK4/6 inhibitors in ER-positive breast cancer models.Semantic proximity Read ↗

Inhibition of the PI3K Pathway: Hope We Can Believe in?Semantic proximity Read ↗

Acquired resistance to CDK4/6 inhibition is associated with dysregulation of multiple pathways including cyclin D-CDK4/6-RB, EGFR/HER, AKT/mTOR and IFN signalingSemantic proximity Read ↗

Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.